Biotechnology is one of the most rapidly growing sectors in Boston. While the science and R&D behind new drug therapies, treatments, and medical devices might not be accessible to the layperson, the economic impact of this sector remains crucially important. 

On September 27th, Jonathan Fleming of Q-State Biosciences, a company that utilizes revolutionary technologies, such as stem cell research, optogenetics, and advanced optical imaging, to help create models of neuronal and cardiac diseases. The company's research program is consistently at the cutting edge of precision medicine—the ability to tailor treatments to a particular patient. Mr. Fleming will join us to discuss effective strategies for maintaining growth and, above all, increasing options and improving health outcomes for patients.

A lifelong entrepreneur, Mr. Fleming will discuss how to successfully build and scale business models to ensure the best chance of success in a highly-regulated, innovative field with ever-growing sources of competition.

About the Speaker

Jonathan Fleming is the President and CEO of Q-State Biosciences, an early stage privately funded neuroscience company in Cambridge, MA. Mr. Fleming has been a life science entrepreneur for more than 31 years, starting and financing growth companies in the United States, Europe, Israel and Asia.  Since 1996, he has been the Managing Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science investments. During his career, he co-founded several neuroscience companies.

Mr. Fleming has been a Senior Lecturer at the MIT Sloan School of Management since 2002, where he co-teaches a class on business strategy for life science managers.  He holds a Master’s degree in Public Administration from Princeton University’s Woodrow Wilson School of Public and International Affairs, and a Bachelor’s degree in Political Science from the University of California, Berkeley.